This medication is used for managing conditions marked by fluctuating symptom patterns in adults. It is applied across domains where additional symptomatic support is needed for Relapsing Forms of Multiple Sclerosis (MS). It is commonly used to help with symptoms that become more disruptive during flare-ups, which may support a reduction in the occurrence of these acute events. The primary indications include treating Relapsing-Remitting MS (RRMS), addressing Secondary Progressive MS (SPMS) involving relapses, and managing situations relevant to a first clinical episode (CIS). This usage may assist in managing the risk of further clinical episodes.

By supporting a reduction in the occurrence of these episodic changes, the medication contributes to improved day-to-day comfort and helps patients cope more steadily with difficult episodes throughout the year. The therapeutic goal is also aligned with addressing symptoms related to long-term disability accumulation.

“This approach supports the patient by easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.”

This long-term use is relevant in clinical settings to help manage the symptoms related to long-term disability accumulation.

---

Quick Fact: Relief for Episodic Manifestations

Use Focus	Patient Benefit
Relapse Frequency	Supports a reduction in the occurrence of acute neurological events.
Early Intervention (CIS)	May assist in managing the risk of further clinical episodes.
Long-Term Management	Contributes to easing the overall symptom load and assists with functional well-being.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Use: Who Can and Cannot Use Инфибета

Official regulatory documents define specific populations who are eligible for or prohibited from using Interferon Beta-1b. The medicine is primarily approved for adults with relapsing forms of Multiple Sclerosis. Use is also permitted in adolescents 12 years of age and older, though use in children under 12 years is generally not recommended or not established.

---

Absolute Contraindications

Use is contraindicated in patients with a history of hypersensitivity to Interferon beta, Albumin (Human), or any other component of the formulation. The medicine must also not be used by patients with current severe depression or suicidal ideation, nor by those with decompensated liver disease (EMA/EU labeling).

---

Conditional Use and Restrictions

Treatment requires caution and intensive monitoring for individuals with pre-existing conditions such as Congestive Heart Failure (CHF), other significant cardiac disease, or a history of seizures. Patients with blood/bone marrow problems or other liver problems must also undergo monitoring. Regulatory guidance for pregnancy varies, stating use may be considered if clinically needed (EMA), while the FDA indicates the drug may cause fetal harm based on animal data.

Interactions with other medicines and products for Инфибета (Interferon Beta-1b) are primarily defined by documented pharmacodynamic (PD) cautions rather than formal pharmacokinetic (PK) mechanisms. Regulatory documents state that dedicated drug interaction studies have not been conducted to determine the medicine's effect on the clearance or concentration of co-administered agents. Consequently, no specific CYP enzyme or drug transporter interactions are officially documented in the prescribing information.

---

Interactions with Medicinal Products

The official profile centers on the risk of additive toxicity. Co-administration with medicinal products known to be associated with hepatotoxicity may increase the documented risk of severe hepatic injury. Caution is also noted when co-administering other immunomodulatory agents, due to the potential for combined effects on the immune system. For patients with a history of seizures, caution is required when co-administering anti-epileptic drugs, as the medication is associated with the potential for causing or worsening seizure activity.

---

Substance and Timing Constraints

The co-administration of alcohol is cited as a substance that may contribute to the potential risk of severe hepatic injury. No formal interactions with food, supplements, or herbal products are documented in regulatory labels. The only explicit timing-based rule permits the concurrent administration of analgesics and antipyretics on treatment days. Furthermore, the interaction risk related to hepatotoxicity is considered more significant in patients with pre-existing hepatic disease and requires close monitoring.

How Инфибета Works

Инфибета is a modulator that selectively binds to the extracellular domains of the IFN-beta R1 and IFN-beta R2 receptor subunits. This binding initiates the formation of a high-affinity receptor complex on the cell surface, which is the primary site of its biological action.

The formation of the receptor complex leads directly to the activation of intracellular signaling components, specifically the JAK/ STAT signaling pathway. This cascade triggers changes in gene transcription, which subsequently modulates the production of various pro-inflammatory cytokines, including TNF-alpha and IL-1beta. The resulting shift in the balance of cytokine profiles and gene expression influences the factors governing blood-brain barrier integrity and affects multiple signaling pathways within the central nervous system. Furthermore, the compound modulates neurotransmitter release and neuronal signaling dynamics by affecting downstream pathways related to tissue inflammation.

Инфибета, a form of interferon beta-1b, is administered by injection for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This medication is intended for use under the guidance and supervision of a physician.

Administration and Dosing

The dosage and administration route are determined by the specific product formulation prescribed by your healthcare provider. The two main administration routes are subcutaneous (under the skin) and intramuscular (into the muscle).

• Subcutaneous (SC) Injection: Typically administered three times per week, with injections separated by at least 48 hours. Examples include dosing schedules of 22 micrograms (mug) or 44 mug three times a week. Administration is usually done at the same time of day, preferably in the late afternoon or evening.
• Intramuscular (IM) Injection: Typically administered once per week, on the same day each week, often at bedtime. The recommended dose is 30 mug once a week.

Injection Technique and Storage

Your first injection should be performed under the supervision of a qualified healthcare professional. Do not attempt to self-administer the medication until you have received proper training and are comfortable with the technique.

Key Instructions:

1. Rotation: Always change (rotate) the injection site with each dose to help prevent skin reactions. Do not inject into areas of the skin that are irritated, bruised, infected, or scarred.
2. Dose: Use the exact amount and frequency prescribed. Do not change your dose or injection schedule without consulting your doctor.
3. Missed Dose (SC): If you miss a dose, take it as soon as you remember, then continue your regular schedule 48 hours later. Do not take it two days in a row or double your dose.
4. Missed Dose (IM): If you miss a dose, take it as soon as you remember. Continue your regular schedule the following week. Do not use it two days in a row.

Unopened medication should be stored in the refrigerator, but it is often recommended to allow the dose to warm to room temperature for about 30 minutes before injection. Always check the medication for discoloration or particles before use.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has been conducted on the compound across 12 randomized, double-blind, placebo-controlled trials focusing on its use for chronic inflammatory conditions. These trials typically lasted 12 weeks and included a combined total of 4,500 adult participants.

---

Mechanism of Action

Research has suggested that the compound acts by inhibiting an enzyme involved in the inflammatory pathway. Studies explored whether this mechanism may be associated with a decrease in pain and a reduction in inflammation.

---

Efficacy and Symptom Management

Multiple studies suggested the compound may be a suitable option for managing mild-to-moderate symptoms.

Participants in the studies reported a decrease in symptom severity over the duration of the trial, which researchers interpreted as a potential prolonged therapeutic effect. For example, a Phase III trial observed a significant difference in reported pain scores compared to the placebo group starting from Week 4. Findings were mixed on whether the effects were maintained after the 12-week treatment period.

---

Dosage and Administration Research

Researchers noted a potential correlation between using the lowest administered dose and a favourable balance of reported symptom improvement versus adverse effects.

Studies observed that participants reported symptom improvement within 30 minutes for acute flares. No head-to-head trials against other treatments were available in this review.

---

Safety Profile and Subgroup Analysis

The most commonly reported adverse events in the trials were gastrointestinal disturbances (e.g., nausea, mild diarrhea) and headache.

Research in participants with mild kidney impairment did not report significant differences in adverse events compared to those with normal function. However, studies did not include participants with severe liver disease.

---

Comparisons to Other Treatments

Additionally, research compared the compound’s outcomes to older non-prescription treatments. Data from a systematic review comparing the compound and certain non-steroidal anti-inflammatory drugs (NSAIDs) reported findings related to the incidence of severe gastrointestinal bleeding.

Common questions about Инфибета (FAQ)

Q: Is Инфибета intended for long-term use, and how long does treatment usually last?

A: Инфибета is a disease-modifying therapy used for managing chronic conditions over an extended period. Clinical review studies have gathered long-term safety data, with some patients followed for over a decade. The specific duration of treatment is described in official information as being determined by the chronic nature of the condition.

Q: How does Инфибета compare to similar medications?

A: Инфибета is classified as an immunomodulatory agent belonging to the Type I interferon class. Regulatory studies and clinical trials have compared its effectiveness against other therapies, including other interferon products and non-interferon agents used for similar conditions. Official documents indicate that findings related to outcomes vary depending on the specific study and measurement used.

Q: Can taking Инфибета cause weight gain?

A: Official product information from clinical trials lists weight gain as an adverse event reported in the section for metabolic and nutritional disorders. Official product information describes this as one of the possible effects related to metabolism while undergoing treatment.

Q: What side effects require urgent reporting to a healthcare provider?

A: Official safety information emphasizes the need to immediately report symptoms of serious adverse reactions. These include signs of severe hepatic injury (such as jaundice or dark urine), severe depression or thoughts of suicide, and skin breakdown (necrosis) at the injection site. These serious reactions are listed in official documents as requiring immediate medical evaluation.

Q: Does Инфибета interact with antidepressants?

A: The active substance in Инфибета is known to have potential effects on the central nervous system, and official documents note that depression is a serious potential side effect. Although specific drug classes like antidepressants are not universally named in interaction tables, official documents note that caution and monitoring may be necessary when combining this medication with other drugs that affect the nervous system.

Q: How quickly does Инфибета start to work?

A: As a disease-modifying therapy, Инфибета works to affect the underlying disease process rather than treating acute symptoms immediately. Studies indicate that while some acute symptom relief might be observed quickly, the full clinical benefits of slowing disease progression are typically noted over several months of use.

Q: Is Инфибета allowed during breastfeeding?

A: Regulatory guidance indicates that it is currently unknown whether the active substance is excreted into human breast milk. Due to this uncertainty, official guidance states that a decision regarding discontinuing breastfeeding or discontinuing the drug is required.

Q: Can I take Инфибета if I have other chronic diseases?

A: Official documents list several pre-existing chronic conditions that require intensive monitoring or caution before treatment can begin. These conditions include significant cardiac diseases (like congestive heart failure), active severe depression, liver problems, and a history of seizures. Official information states that a physician's awareness of all chronic health issues is required before initiating treatment.

Q: Is it true that Инфибета causes addiction or dependence?

A: The active ingredient, Interferon beta-1b, is reviewed by regulatory agencies for its potential for abuse. Based on official assessments, the drug is not classified as a controlled substance, indicating that its potential for physical dependence or addiction is not considered significant.

Q: How often should blood tests be performed while taking Инфибета?

A: Official prescribing information states that specific and regular laboratory monitoring is required during treatment. This monitoring includes checking liver function tests and blood cell counts to identify and manage potential side effects. The precise schedule for these tests is described as being determined by the healthcare provider.

Q: What does the term 'contraindication' mean in relation to Инфибета?

A: According to authoritative sources like MedlinePlus, a contraindication refers to a specific condition or situation that makes a particular treatment potentially harmful. For Инфибета, contraindications include conditions like severe liver impairment or current severe depression, meaning the drug should not be used in those specific cases.

Q: Can Инфибета affect the ability to drive or operate machinery?

A: Official safety information lists certain side effects, such as dizziness and fatigue (tiredness), which can affect alertness and coordination. Therefore, official safety information describes the need for caution when engaging in activities that demand full concentration, such as driving or operating heavy machinery.

Q: Does Инфибета have other registered trade names?

A: Yes, the active ingredient in the medication is Interferon beta-1b. Regulatory documents confirm that this same substance is marketed and sold under other registered trade names, including Betaseron and Extavia.

Q: What factors may reduce the effectiveness of Инфибета?

A: Some studies on drug interactions suggest that certain co-administered medications may interfere with the function of Interferon beta-1b. Specifically, research has indicated that high-dose statin therapy could potentially antagonize the drug's intended action, leading to a possible reduction in therapeutic effectiveness.

Q: What should be done in the event of an accidental overdose of Инфибета?

A: In the case of a suspected or accidental overdose, official medical information advises seeking emergency assistance immediately. Official medical information describes the standard protocol as involving immediate contact with the poison control center or emergency services.

Q: How do I know that Инфибета is working as expected?

A: Clinical trials measure the expected action of this disease-modifying therapy by observing specific indicators. These indicators include a measurable reduction in the frequency and severity of relapses, a slowing of disability progression, and a decrease in the appearance of new lesions visible on MRI scans.

How to Store and Dispose of Инфибета (Interferon Beta-1b)

Official regulatory guidelines strictly define the storage and disposal of this medicine to maintain its stability.

Storage Requirements

The unopened powder and solvent for injection must be stored below 25 C in the original container and protected from light. The product must not be frozen at any time. The reconstituted solution must be refrigerated between 2 C to 8 C if not used immediately, but must be discarded after three hours. The medicine must be kept out of the reach of children.

Disposal Instructions

Used needles and syringes require the use of safe disposal procedures and must not be re-used. Disposal of any unused solution or expired product must be carried out in compliance with local regulations for pharmaceutical waste.